Shire’s new drug sales offset 74% decline in Adderall
Declining sales of its now off-patent drug Adderall XR continue to weigh on Shire, the speciality pharmaceutical group, although strong growth in sales of new drugs…
source : traxfer.ft.com
Related News:
- Kidney Cancer Drug Shows Promising Results
- AM: Drug for Fibromyalgia Boosts Multiple Outcomes (CME/CE)
- Access Pharmaceuticals Initiates Program Applying Cobalamin Platform To SiRNA Drug Delivery
- Auxilium Announces U.S. Food And Drug Administration Approval For XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
- Possible New Drug Target For Iron Deficiency, Overload
- Targeted Oral Drug Pazopanib Slows Progression Of Advanced Kidney Cancer
- Using Zebrafish As A Novel Platform For Drug Development
- PSivida CEO To Discuss Ocular Drug Delivery In Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 In London
- Abnormal Lipid Levels Common in Teens
- FDA Adds Cardio Warnings to Weight Loss Drug
Details :
Submited at Saturday, October 31st, 2009 at 12:00 am on Pharmaceutical by admin
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...
















